Learning Objectives

• Evaluate risk-stratified treatment algorithms in PV and ET to support consistent clinical pathway development and coverage decision-making across academic and community practice settings
• Differentiate first-line and second-line cytoreductive strategies, including interferon-based and non-interferon approaches, in PV and ET based on evidence-based sequencing considerations, patient selection criteria, and clinical trial data
• Apply long-term management strategies in PV and ET, including assessment of treatment durability, tolerability, symptom burden, and PROs, to optimize clinical pathway design and payer alignment

Supported by an educational grant from PharmaEssentia USA Corporation.

This session explores how organizations can translate clinical evidence into actionable pathways that deliver measurable value. Learn strategies for balancing efficacy, safety, and cost, while defining and tracking value-based metrics that resonate with clinicians, administrators, and payers. 

JCP Clinical Pathways Category: Business + Outcome Measurements

Clinical pathways play a critical role in both care standardization and financial performance. This session examines how organizations can align clinical innovation with fiscal responsibility, covering budgeting, reimbursement considerations, stakeholder buy-in, and demonstrating return on investment. 

JCP Clinical Pathways Category: Business

This session is sponsored by Johnson & Johnson.

Explore how data, real-world evidence, and AI are reshaping pathway design and implementation. This session highlights practical approaches to building dynamic, data-driven pathways while addressing interoperability, governance, and clinician adoption challenges. 

JCP Clinical Pathways Category: Infrastructure & Innovation 

Successful pathways depend on effective implementation. This session focuses on managing change across complex care environments, engaging clinicians, and ensuring ethical, consistent application of pathways while preserving appropriate clinical judgment. 

JCP Clinical Pathways Category: Consistency & Ethics 

Learning Objectives

• Describe standard‑of‑care management of CLL and MCL and the integration of next‑generation BTKis into guideline‑concordant clinical pathways
• Differentiate BTKis by mechanism, efficacy, and safety to select patient‑appropriate agents at defined clinical pathway decision points
• Apply fixed‑duration and continuous BTKi‑based regimens for CLL and MCL within clinical pathways while accounting for the non‑interchangeability of agents and common payer coverage restrictions
• Implement pathway‑based processes for CLL and MCL in community practice to monitor toxicities, mitigate CV risk, and manage treatment interruptions or switching with BTKis

Supported by an educational grant from BeOne. 

Learning Objectives

• Apply current evidence and guideline-based criteria to differentiate NETs from NECs and incorporate these distinctions into clinical pathway development, including diagnostic assessment and risk stratification
• Evaluate the role of emerging biomarkers, including DLL3, in EP-NEC and assess their potential to inform patient identification and biomarker-driven therapeutic strategies within clinical pathways
• Interpret recent clinical trial data and evolving evidence for approved and investigational therapies in EP-NEC to support evidence-based treatment selection and sequencing
• Integrate emerging therapeutic approaches into clinical pathways for EP-NEC, considering real-world evidence, value-based care principles, and access considerations across diverse healthcare stakeholders

This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

As pathways increasingly influence treatment decisions, collaboration between pharma and providers is evolving. This session explores emerging partnership models that support evidence-based care, transparency, and value-based outcomes—while aligning clinical goals with business realities. 

JCP Clinical Pathways Category: Business

This session examines how evolving healthcare policy and regulatory frameworks shape clinical pathway design and adoption. Attendees will gain insight into navigating reimbursement models, compliance requirements, and accountability measures—while maintaining flexibility to support innovation and value-based care. 

JCP Clinical Pathways Category: Business

Patient-centered pathways require more than clinical consensus. This session explores practical strategies for incorporating patient perspectives into pathway development, improving shared decision-making, addressing equity, and ensuring pathways align with patient values, preferences, and real-world experiences. 

JCP Clinical Pathways Category: Consistency & Ethics

Learning Objectives

• Integrate evidence-based biomarker guidelines into standardized clinical pathways to guide systemic therapy selection across solid tumor settings
• Apply pathway-driven protocols to optimize the safe use and monitoring of immuno-oncology agents, antibody-drug conjugates, and subcutaneous immune checkpoint inhibitors
• Implement interdisciplinary clinical pathway models to promote guideline-concordant, patient-centered treatment planning across practice settings

This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Clinical Pathways NEXT (CP NEXT) is the year-round extension of the Clinical Pathways Congress, designed to sustain engagement beyond the annual event and convene pathway leaders around the issues shaping pathway development and decision-making.

It provides a consistent forum for high-level dialogue, alignment on best practices, and advancement of pathway strategy throughout the year.

This session focuses on the financial mechanisms driving pathway innovation. Learn how contracting strategies, incentive structures, and shared savings models can support pathway adoption, align stakeholders, and advance value-based care across healthcare systems. 

JCP Clinical Pathways Category: Business

These accredited educational sessions offer a comprehensive look into the rapidly evolving healthcare landscape, providing the knowledge and skills necessary to thrive in a value-based care environment in which clinical pathways are a key component to driving precision and optimization of patient care.

Clinical alignment can create meaningful strategic and financial value. This session explores how organizations are leveraging pathways to drive differentiation, strengthen partnerships, and unlock new revenue opportunities—while maintaining clinical integrity and trust. 

JCP Clinical Pathways Category: Business